Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGRX-678 in Chronic Myeloid Leukemia
NCT06088888Phase 1Recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TGRX-678 in chronic myeloid leukemia (CML), sponsored by Shenzhen TargetRx. Primary endpoints: Recommended dose for expansion at 1 year, Dose-limiting toxicity at 28 days and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
TGRX-678
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06088888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088888.